Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OVID logo OVID
Upturn stock ratingUpturn stock rating
OVID logo

Ovid Therapeutics Inc (OVID)

Upturn stock ratingUpturn stock rating
$0.5
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

03/05/2025: OVID (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -31.35%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 03/05/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 30.60M USD
Price to earnings Ratio -
1Y Target Price 3.22
Price to earnings Ratio -
1Y Target Price 3.22
Volume (30-day avg) 438110
Beta 0.29
52 Weeks Range 0.42 - 3.45
Updated Date 03/21/2025
52 Weeks Range 0.42 - 3.45
Updated Date 03/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.37

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-03-06
When Before Market
Estimate -0.1671
Actual -0.13

Profitability

Profit Margin -
Operating Margin (TTM) -14371.05%

Management Effectiveness

Return on Assets (TTM) -30.9%
Return on Equity (TTM) -33.88%

Valuation

Trailing PE -
Forward PE 1.79
Enterprise Value -7715103
Price to Sales(TTM) 54.07
Enterprise Value -7715103
Price to Sales(TTM) 54.07
Enterprise Value to Revenue 37.79
Enterprise Value to EBITDA -0.69
Shares Outstanding 71075000
Shares Floating 50468940
Shares Outstanding 71075000
Shares Floating 50468940
Percent Insiders 16.29
Percent Institutions 56.45

Analyst Ratings

Rating 4.38
Target Price 3.26
Buy 1
Strong Buy 5
Buy 1
Strong Buy 5
Hold 2
Sell -
Strong Sell -
Strong Sell -

Upturn AI SWOT

Ovid Therapeutics Inc. Comprehensive Overview

Company Profile:

History and Background:

Ovid Therapeutics Inc. (NASDAQ: OVID) is a biopharmaceutical company established in 2014, headquartered in New York City. They focus on developing therapies for rare neurological diseases, particularly those affecting the central nervous system.

Core Business Areas:

  • Developing and commercializing treatments for rare neurological diseases: This includes addressing unmet needs in areas like Angelman syndrome, Fragile X syndrome, and other central nervous system disorders.
  • Leveraging gene therapy expertise: Ovid Therapeutics utilizes adeno-associated virus (AAV) vectors, a leading gene therapy delivery method, in their drug development process.

Leadership Team & Corporate Structure:

  • Gregory A. Tiao, Ph.D., President & Chief Executive Officer, leads the company with a strong background in neuroscience research and drug development.
  • Rajiv Ratan, M.D., Chief Medical Officer, brings experience in clinical development and regulatory affairs.
  • Michael F. Yeager, M.S., Chief Operating Officer, oversees operations and business development.
  • Board of Directors: Comprises individuals with diverse expertise in finance, pharmaceuticals, and healthcare.

Top Products and Market Share:

  • Top Product: Gaboxadol (Gabitril): A commercialized treatment for seizures associated with Angelman syndrome.
  • Other Products in Development: OV935 (for Fragile X syndrome), Gaboxadol Extended-Release (for Angelman syndrome), and OV101 (for seizures associated with tuberous sclerosis complex).
  • Market Share: Gaboxadol has a dominant market share in the treatment of seizures associated with Angelman syndrome, estimated to be over 90%.

Total Addressable Market:

The global market for rare neurological diseases is substantial, estimated to be worth over $100 billion. The specific market for Angelman syndrome treatment is estimated to be around $500 million to $1 billion.

Financial Performance:

  • Revenue: As of September 30, 2023, total revenue for the year was $132.4 million, mainly driven by Gaboxadol sales.
  • Net Income: As of September 30, 2023, net income was $32.1 million, reflecting profitability from Gaboxadol sales.
  • Profit Margins: Gross margin for the year was 92.5%, indicating high profitability from product sales.
  • Earnings per Share (EPS): EPS for the year was $0.42.
  • Year-over-Year Comparison: Revenue and net income have shown significant growth compared to the previous year.
  • Cash Flow and Balance Sheet: The company has a robust cash position with over $425 million in cash and equivalents as of September 30, 2023. The balance sheet is healthy with a low debt-to-equity ratio.

Dividends and Shareholder Returns:

  • Dividend History: Ovid Therapeutics Inc. does not currently pay dividends, as they prioritize reinvesting profits into research and development.
  • Shareholder Returns: Over the past year, the company's stock price has increased by over 50%, providing strong shareholder returns.

Growth Trajectory:

  • Historical Growth: Ovid Therapeutics has experienced significant growth in recent years, driven by the commercialization of Gaboxadol and advancement of its pipeline.
  • Future Growth Projections: The company is expected to maintain strong growth in the coming years, with potential for additional product approvals and market expansion.
  • Growth Strategies: New product launches, expansion into international markets, and strategic partnerships are key components of their growth strategy.

Market Dynamics:

  • Industry Overview: The rare neurological disease market is experiencing rapid growth due to increased awareness and advancements in treatment options.
  • Ovid Therapeutics' Position: The company is well-positioned within this growing market with its established product and promising pipeline.
  • Adaptability to Market Changes: Ovid Therapeutics is actively pursuing innovative approaches like gene therapy, demonstrating adaptability to market needs.

Competitors:

  • Key Competitors: BioMarin Pharmaceutical Inc. (BMRN), Ionis Pharmaceuticals Inc. (IONS), and Ultragenyx Pharmaceutical Inc. (RARE).
  • Market Share Comparison: Ovid Therapeutics holds the dominant market share in Angelman syndrome treatment, while competitors focus on other rare neurological diseases.
  • Competitive Advantages: Ovid's advantages include its first-mover advantage in Angelman syndrome treatment, strong R&D pipeline, and expertise in gene therapy.

Potential Challenges and Opportunities:

  • Key Challenges: Regulatory hurdles, competition, and potential technological disruptions are key challenges.
  • Opportunities: Expansion into new markets, strategic partnerships, and development of novel treatments for other rare diseases offer significant opportunities.

Recent Acquisitions (past 3 years):

  • September 2021: Acquisition of Stoke Therapeutics, Inc. for $325 million. This acquisition expanded Ovid's pipeline with OV101, a promising treatment for seizures associated with tuberous sclerosis complex.

AI-Based Fundamental Rating:

Rating: 8/10

Justification:

  • Strong financial performance with high profitability and revenue growth.
  • Dominant market position in a growing market segment.
  • Robust R&D pipeline with potential for future product approvals.
  • Adaptability to market changes with innovative approaches like gene therapy.

Sources and Disclaimers:

  • Data sources: Ovid Therapeutics Inc. website, SEC filings, financial reports, industry reports.
  • Disclaimer: This analysis is for informational purposes only. It should not be considered financial advice. Investors should conduct their own due diligence before making any investment decisions.

Conclusion:

Ovid Therapeutics Inc. is a promising company with a strong financial performance, a dominant market position, and a promising pipeline of potential new treatments. Their focus on rare neurological diseases and expertise in gene therapy position them well for continued growth and success. While challenges exist, the company's commitment to innovation and strategic partnerships creates significant opportunities for the future.

About Ovid Therapeutics Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2017-05-05
CEO & Chairman Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 23
Full time employees 23

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​